Full Year Trading Update

Induction Healthcare Group PLC
29 April 2024
 

Induction Healthcare Group PLC

 

("Induction", the "Company", or the "Group"

·     

·     

·     

·     

 

* Adjusted EBITDA is Operating result from continuing operations before depreciation (£0.1m), amortisation (£4.3m) and net of non-cash/ non-operating items (£0.2m)

 

·     

·     

·      Achieved objective of self-sustaining growth and cash flow breakeven

·     

Further integrate Zesty with Oracle Cerner and widely-used diagnostic booking systems (Cris and Soliton);

Enhance Form Builder module to support waitlist validation; and

Build new functionality, such as digitising maternity records.

·     

·     

·     

 

Enquiries

 

Induction

Christopher Samler, Chair

Paul Tambeau, Chief Executive Officer

 

+44 (0)7712 194092

+44 (0)7983 104443


 

 

 

Singer Capital Markets (Nominated Adviser and Broker)

+44 (0)20 7496 3000

 

Philip Davies

Alaina Wong

Jalini Kalaravy

 

 

 

About Induction - www.inductionhealthcare.com

Induction (AIM: INHC) Induction delivers a suite of software solutions that transforms care delivery and the patient journey through hospital. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems. 

 

Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings